- Tytuł:
- Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
- Autorzy:
- Źródło:
- In The Lancet Infectious Diseases January 2022 22(1):97-109
Czasopismo naukowe